All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
BEIJING – Yisheng Biopharma Co. Ltd., of Beijing, said it has inked a pact with U.S. biotech Tavotek Biotherapeutics, of Ambler, Pa., to co-develop a combination therapy with Yisheng’s YS-ON-001/002 and Tavotek’s Tavo-301/303 the companies hope could prove a more efficacious cancer treatment than the popular anti-PD-1/PD-L1 monotherapies. YS-ON-001 and YS-ON-002 are potent agonists of TLR3, MDA5 and RIG-I pathways. Meanwhile, Tavo-301/303 is a series of novel multispecific antibody-based immuno-oncology assets.